PRDX2 and lung carcinoma: As seen from Table 2, the preclinical validation of the QDEM-based and Luminex bead-based 3-plex immunoassays for AMBP, PRDX2, and PARK7 markers as techniques for the diagnosis of lung cancer yielded practically identical results for both of them.